Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2023

Open Access 03-11-2022 | Hematuria | Original article

A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry

Authors: Makoto Nasu, Naoki Nakagawa, Shigeo Hara, Junko Yano, Yuka Kurokawa, Nao Nakamura, Hitoshi Yokoyama, Akira Shimizu, Hitoshi Sugiyama, Hiroshi Sato, Kei Fukami

Published in: Clinical and Experimental Nephrology | Issue 2/2023

Login to get access

Abstract

Background

Fabry disease (FD) is an X-linked inherited disease where renal complications are associated with a poor prognosis. However, little is known about the prevalence of Fabry nephropathy (FN) in patients with chronic kidney disease (CKD). We extracted FN data from the Japan Renal Biopsy Registry, analyzed the prevalence of FN, and examined the correlation between clinical characteristics and renal involvement according to sex differences and hemi- and heterozygosity in patients with FD.

Methods

A total of 38,351 participants who underwent renal biopsy were retrospectively enrolled, and FN was determined. The clinical characteristics of FD patients were examined based on sex differences.

Results

Twenty-nine patients (0.076%) (19 males and 10 females, mean age: 43.7 ± 15.5 years old) were diagnosed with FN. Median estimated urinary protein (UP) and mean eGFR levels were 0.9 [interquartile range (IQR) [0.7–1.6] g/gCr and 67.1 ± 36.8 mL/min/1.73 m2, respectively. Mean systolic blood pressure (SBP) was 126.4 ± 17.1 mmHg and diastolic blood pressure was 76.1 ± 12.6 mmHg. An inverse correlation between eGFR and logarithm UP levels was observed (r2 = 0.23, p = 0.02), SBP was positively associated with logarithm UP (r2 = 0.34, p = 0.004) overall and inversely associated with eGFR (r2 = 0.25, p = 0.007) regardless of sex, and SBP was an independent determinant of proteinuria (p = 0.004) and eGFR (p = 0.007).

Conclusions

The prevalence of biopsy-proven FN was 0.076%. Since SBP is associated with eGFR regardless of zygosity, strict SBP control might be necessary to prevent progression to end-stage kidney disease in both male and female patients with FN.
Appendix
Available only for authorised users
Literature
13.
go back to reference Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis. 2007;50(6):927–37.CrossRef Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis. 2007;50(6):927–37.CrossRef
14.
go back to reference Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRef Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRef
15.
go back to reference Uemura O, Yokoyama H, Ishikura K, Gotoh Y, Sato H, Sugiyama H, et al. Performance in adolescents of the two Japanese serum creatinine based estimated glomerular filtration rate equations, for adults and paediatric patients: a study of the Japan renal biopsy registry and Japan kidney disease registry from 2007 to 2013. Nephrology (Carlton). 2017;22(6):494–7. https://doi.org/10.1111/nep.12982.CrossRef Uemura O, Yokoyama H, Ishikura K, Gotoh Y, Sato H, Sugiyama H, et al. Performance in adolescents of the two Japanese serum creatinine based estimated glomerular filtration rate equations, for adults and paediatric patients: a study of the Japan renal biopsy registry and Japan kidney disease registry from 2007 to 2013. Nephrology (Carlton). 2017;22(6):494–7. https://​doi.​org/​10.​1111/​nep.​12982.CrossRef
17.
go back to reference Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, et al. Results of Fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a Northern Taiwan medical center. Kidney Blood Press Res. 2018;43(5):1636–45. https://doi.org/10.1159/000494678.CrossRef Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, et al. Results of Fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a Northern Taiwan medical center. Kidney Blood Press Res. 2018;43(5):1636–45. https://​doi.​org/​10.​1159/​000494678.CrossRef
19.
go back to reference Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600–7. https://doi.org/10.1093/ndt/gfm848.CrossRef Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600–7. https://​doi.​org/​10.​1093/​ndt/​gfm848.CrossRef
Metadata
Title
A nationwide cross-sectional analysis of biopsy-proven Fabry nephropathy: the Japan Renal Biopsy Registry
Authors
Makoto Nasu
Naoki Nakagawa
Shigeo Hara
Junko Yano
Yuka Kurokawa
Nao Nakamura
Hitoshi Yokoyama
Akira Shimizu
Hitoshi Sugiyama
Hiroshi Sato
Kei Fukami
Publication date
03-11-2022
Publisher
Springer Nature Singapore
Published in
Clinical and Experimental Nephrology / Issue 2/2023
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-022-02287-w

Other articles of this Issue 2/2023

Clinical and Experimental Nephrology 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine